Protagenic Therapeutics, Inc.(PTIX)Earnings, Financials & Key Ratios

Key Thesis Takeaways

• Protagenic Therapeutics remains a high-risk, pre-revenue clinical-stage entity whose financial viability is entirely contingent upon external capital infusions to sustain its R&D programs.
• The company's reliance on debt and equity financing has resulted in a $2.4 million equity deficit as of 2025Q4, signaling significant solvency concerns.
• Investors should monitor the firm's ability to secure non-dilutive funding, as the current cash runway is severely constrained by recurring quarterly operating losses often exceeding $1 million.